Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Kura Oncology Receives FDA Clearance for IND Application of Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

NextEdge Admin

08 Aug 2024

1 min 57 sec

Kura Oncology, a clinical-stage biopharmaceutical company dedicated to advancing precision medicines for cancer treatment, announced that the FDA has cleared its Investigational New Drug (IND) application for ziftomenib, a potent and selective menin inhibitor, for advanced gastrointestinal stromal tumors (GIST). The company will begin a Phase 1 study of ziftomenib combined with imatinib, a targeted therapy for GIST, in early 2025.

“This milestone marks the first IND clearance of a menin inhibitor for GIST, offering new hope for patients with limited treatment options,” said Troy Wilson, Ph.D., J.D., President and CEO of Kura Oncology. “While imatinib is the frontline treatment for GIST, resistance often develops. Preclinical data suggest ziftomenib can resensitize patients to imatinib, leading to deep, durable responses. We are excited to present our preclinical findings at an upcoming scientific meeting and to begin clinical trials early next year.”

GIST, the most common form of sarcoma, is characterized by KIT-dependent tumors. Though KIT inhibitors like imatinib improve patient outcomes, resistance limits their efficacy. The menin-MLL complex regulates KIT expression, and menin inhibitors show additive effects with imatinib. Preclinical models indicate that combining ziftomenib with imatinib may resensitize resistant GIST patients, prompting the planned proof-of-concept study.